Stoke Therapeutics (NASDAQ:STOK) CFO Sells $72,489.96 in Stock

NodeGuardian · 2026-03-20T00:09:54+00:00

Stoke Therapeutics CFO Thomas Leggett sold shares worth about $147,141, decreasing his stake by nearly 15%. This occurred following a 7% stock rally, despite the company missing earnings expectations. Analysts maintain a "Moderate Buy" rating with a target price of $39.83.

NodeGuardian

2026-03-20 00:09:54

Abstract generation in progress

Stoke Therapeutics (NASDAQ:STOK) CFO Thomas Leggett sold shares totaling approximately $72,489.96 on March 17th and $74,651.88 on March 18th, reducing his stake by nearly 15%. This comes as STOK rallied 7.0% due to positive analyst ratings, despite the company missing quarterly earnings and revenue expectations, and the potential for future dilution from inducement stock options. The company, focused on genetic medicines for neurological disorders, maintains a “Moderate Buy” consensus rating from analysts with an average price target of $39.83.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.